TrialPathology oncology research : POR2018

Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study).

Tamás Schneider et al.PubMed ↗Publisher ↗

No numbers read from the abstract.